hsCRP Can ID Cardiovascular Risk in Women Without Modifiable Risk Factors
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 8, 2025 -- High levels of high-sensitivity C-reactive protein (hsCRP) can identify cardiovascular risk among women who do not have any of the four standard modifiable cardiovascular risk factors (SMuRFs): hypertension, dyslipidemia, diabetes mellitus, and smoking, according to a study published online Aug. 29 in the European Heart Journal.
Paul M. Ridker, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues examined the utility of hsCRP to detect cardiovascular risk in SMuRF-less women. hsCRP was measured at baseline among 12,530 initially healthy American women who were followed for first major adverse cardiovascular events (MACEs) over 30 years.
The researchers found that 973 first MACEs were accrued during 30-year follow-up. SMuRF-less women who subsequently suffered a cardiovascular event had significantly higher median baseline hsCRP than those who did not (median, 2.22 versus 1.50 mg/L). The hazard ratios for the primary end point of incident coronary heart disease (CHD) were 1.0 (referent), 1.24 (95 percent confidence interval [CI], 0.89 to 1.74), 1.41 (95 percent CI, 1.02 to 1.96), 1.57 (95 percent CI, 1.14 to 2.16), and 2.23 (95 percent CI, 1.65 to 3.03) for the lowest to highest levels of hsCRP at study entry in age-adjusted analyses; for each increasing quintile of hsCRP, CHD risk increased 21 percent over 30 years. Compared with those with hsCRP <1 mg/L, SMuRF-less women with hsCRP >3 mg/L had a 77, 39, and 52 percent higher risk for CHD events, ischemic stroke events, and total cardiovascular disease events, respectively.
"Our data clearly show that apparently healthy women who are inflamed are at substantial lifetime risk. We should be identifying these women in their 40s, at a time when they can initiate preventive care," Ridker said in a statement.
Several authors disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2025
Read this next
Women Benefit More From Implantable Defibrillators Than Men
TUESDAY, Sept. 2, 2025 -- There is a lower risk of one-year ventricular arrhythmias or death in women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator...
Use of AI Can Help Identify Coronary Thin-Cap Fibroatheromas
TUESDAY, Sept. 2, 2025 -- An artificial intelligence (AI)-based image analysis can identify coronary thin-cap fibroatheromas (TCFAs), which are associated with adverse...
Spironolactone Does Not Reduce Risk for Cardiovascular Morbidity, Mortality in Patients on Dialysis
THURSDAY, Aug. 28, 2025 -- Spironolactone does not reduce a composite outcome of cardiovascular mortality and hospitalization due to heart failure among patients receiving...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.